Roydon Price, Ph.D is a biopharmaceutical advisor and entrepreneur with over 15 years of experience working in drug development. He consults to academics, biotech and venture firms.

Dr. Price has also co-founded two biotech companies based on technology from leading academic laboratories. Acylin Therapeutics was founded to develop new acyl-transferase modulators for cancer and metabolic disease.

His current venture, LQT Therapeutic is developing new therapy for Long QT Syndrome, a genetic disease causing cardiac arrhythmia which is a leading cause of sudden death in adolescents. Prior to these roles, Dr. Price led a team in a successful effort to discover non-obvious drug combinations for immuno-inflammatory disease at CombinatoRx Inc.

Several of these combinations were subsequently developed and clinically tested in rheumatoid arthritis, asthma and osteoarthritis patients.

Dr. Price graduated from Revelle College at UCSD, in La Jolla California and received his PhD in biochemistry and molecular pharmacology from Harvard University. His thesis was focused on how immunosuppressant modulate the immune system.

Later, Dr. Price completed a post-doctoral fellowship and became an instructor in the department of Pediatric Oncology at the Dana Farber Cancer Institute where he worked on signaling pathways that affect key transcription factors in melanocyte differentiation and melanoma growth.